

SAKAR ONCOLOGY PRIVATE LIMITED

AHMEDABAD

STATEMENT OF ACCOUNTS

31.03.2022

A. L. THAKKAR & CO. CHARTERED ACCOUNTANTS

603-607 AARYA EPOCH, OPP. PASSPORT SEVA KENDRA,

NR. VIJAY CROSS ROAD, NAVRANGPURA, AHMEDABAD- 380009

[079-48940856, 9978034283 [R] 26401519, 26408439

Website : althakkar.com Email : info@althakkar.com

Sakar Oncology Private Limited
CIN:- U24297GJ2020PTC113326
Standalone Balance Sheet as at March 31, 2022

(Amount in '000)

Particulars	Notes	As at March 31, 2022	As at March 31, 2021
Assets			
Non-current assets			
Property, plant and equipment	3	-	-
Capital work-in-progress	3	-	-
Other Intangible assets	3	-	-
Non-current financial assets			
Investments	6	-	-
Loans	9	-	-
Other non-current assets	4	-	-
Current assets			
Inventories	5	-	-
Financial assets			
(i) Investments	6	-	-
(ii) Trade receivables	7	-	-
(iii) Cash and cash equivalents	8	20.50	20.50
(iv) Loans	9	-	-
Other current assets	4	-	-
		20.50	20.50
Total assets		20.50	20.50
Equity and liabilities			
Equity			
Equity share capital	10	100.00	100.00
Other equity	11	(852.04)	-852.04
Total equity		(752.04)	-752.04
Liabilities			
Non-current liabilities			
Financial liabilities			
(i) Borrowings	16	772.54	772.54
Provisions	13	-	-
Deferred tax liabilities (net)	14	-	-
		772.54	772.54
Current liabilities			
Financial liabilities			
(i) Borrowings	16	-	-
(ii) Trade payables	17	-	-
(iii) Other financial liabilities	12	-	-
Provisions	13	-	-
Other current liabilities	15	-	-
Liabilities for current tax (net)	18	-	-
		772.54	772.54
Total liabilities		772.54	772.54
Total equity and liabilities		20.50	20.50
The accompanying notes form an integral part of financials statements			

As per our report of even date
For A.L. Thakkar & Co.
Firm Registration No.: 120116W
Chartered Accountants

Sanjiv Shah

Sanjiv Shah
Partner
Membership No. 042264
UDIN : 22042264AJHJMZ16348

Place: Ahmedabad
Date: 20.05.2022



For and on behalf of Board of Directors of
Sakar Healthcare Limited

Sanjay Shah

Sanjay Shah
Director
DIN: 01515296

Place: Ahmedabad
Date: 20.05.2022

Aarsh Shah

Aarsh Shah
Director
DIN: 05294294

Sakar Oncology Private Limited

CIN:- U24297GJ2020PTC113326

Standalone Statement of Profit and Loss for the period ended March 31, 2022

(Amount in '000)

Particulars	Notes	For the year ended March 31, 2022	For the year ended March 31, 2021
Income			
Revenue from operations	20	-	-
Other income	21	-	-
Total income		-	-
Expenses			
Cost of Materials consumed	22	-	-
Changes in inventories of finished goods and work-in-progress	26	-	-
Employee benefits expense	27	-	95
Depreciation and amortization expense	3	-	-
Finance costs	28	-	-
Other expenses	29	-	757
Total expense		-	852
Profit before exceptional items and tax		-	(852)
Exceptional items		-	-
Profit before tax		-	(852)
Tax expense/(credit)	30	-	-
Current Tax		-	-
Adjustment of tax relating to earlier periods		-	-
Deferred tax		-	-
Less: MAT credit entitlement		-	-
Total tax expense		-	-
Profit for the year		-	(852)
Other comprehensive income			
Other comprehensive income not to be reclassified to profit or loss in subsequent periods			
Re-measurement gains (losses) on defined benefit plans		-	-
Income Tax effect		-	-
Other comprehensive income for the year		-	-
Total comprehensive Income for the year		-	(852)
Basic and diluted earnings per equity shares (in `) face value of ` 10 each	32	-	(85.20)
The accompanying notes form an integral part of financials statements			


As per our report of even date
For A.L. Thakkar & Co.
Firm Registration No.: 120116W
Chartered Accountants


Sanjiv Shah
Partner
Membership No. 042264
UDIN : 22042264AJHJMZ4618

Place: Ahmedabad
Date: 20.05.2022



For and on behalf of Board of Directors of
Sakar Healthcare Limited


Sanjay Shah
Director
DIN: 01515296


Aarsh Shah
Director
DIN: 05294294

Place: Ahmedabad
Date: 20.05.2022

Sakar Oncology Private Limited

CIN:- U24297GJ2020PTC113326

Statement of Cash Flows for the year ended March 31, 2022

Particulars	For the year ended March 31, 2022	For the year ended March 31, 2021
Cash flow from operating activities		
Profit before tax as per statement of profit and loss		
Adjustments for:	-	(852)
Depreciation and amortisation	-	-
Interest expense	-	-
Profit on Sale of Mutual Fund	-	-
Unrealised Gain on Mutual Fund	-	-
Amortised Loan Processing Fees	-	-
Changes in other equity	-	-
Other Non-Cash Adjustment	-	-
Provision for doubtful advances (net)	-	-
Operating profit before working capital changes	-	(852)
Movements in working capital :		
(Increase)/decrease in trade receivables	-	-
(Increase)/decrease in inventories	-	-
(Increase)/decrease in financial assets	-	-
(Increase)/decrease in other current assets	-	-
Increase/(decrease) in trade payables	-	-
Increase/(decrease) in other current liabilities	-	-
Increase/(decrease) in provisions	-	-
Increase/(decrease) in short term borrowings	-	-
Cash generated from operations	-	(852)
Direct taxes (paid)/refund (net)	-	-
Net cash inflow / (Outflow) from operating activities (A)	-	(852)
Cash flows from investing activities		
Purchase of property, plant and equipments (Including capital work in progress, capital advances and capital	-	-
Profit on Sale of Mutual Fund	-	-
Purchase of Mutual Fund	-	-
Sale of Mutual Fund	-	-
Capital Advances	-	-
Net cash inflow from investing activities (B)	-	-
Cash flows from financing activities		
Proceeds from issuance of share capital	-	100
Proceeds from borrowing	-	773
Repayment of Borrowing	-	-
Payment of Loan Processing Fees	-	-
Repayment of Current Maturities of Long Term Debt	-	-
Interest paid	-	-
Net cash inflow from financing activities (C)	-	873
Net increase / (decrease) in cash & cash equivalents (A + B + C)	-	21
Cash and cash equivalents at the beginning of the year	21	-
Cash and cash equivalents at the end of the period	21	21
Notes:		
Component of cash and cash equivalents		
Cash on hand	-	-
Balances with scheduled bank	-	-
On current accounts	21	21
Cash and Cash Equivalents at the End of the period	21	21

Summary of significant accounting policies refer note 2.2

(1) The Statement of Cash flows has been prepared under the Indirect method as set out in Ind AS 7 – Statement of Cash flows notified under section 133 of The Companies Act, 2013, read together with paragraph 7 of the Companies (Indian Accounting Standard) Rules 2015 (as amended).

(2) Disclosure required under Para 44A as set out in Ind AS 7 on cash flow statements under Companies (Indian Accounting Standards) Rules, 2015 (as amended) is presented in footnote (a) of note -15.

As per our report of even date

For A.L. Thakkar & Co.
Firm Registration No.: 120116W
Chartered Accountants



Sanjiv Shah
Partner
Membership No. 042264
UDIN : 22042264AJHJN24618



Place: Ahmedabad
Date: 20.05.2022

For and on behalf of Board of Directors of



Sanjay Shah
Director
DIN: 01515296



Aarsh Shah
Director
DIN: 05294294

Place: Ahmedabad
Date: 20.05.2022

Sakar Oncology Private Limited
 CIN: U24297GJ2020PTC113326
 Standalone Statement of Changes in Equity for the year ended March 31, 2022

Particulars	Equity Share Capital	Reserves and surplus			Total
		Share Premium	Retained earning	Deemed Equity Contribution	
Balance as at April 01, 2020	100	-	-	-	100
Profit/(Loss) for the year	-	-	-	-	-
Movement for the year	-	-	-	-	-
Share issue during the year	-	-	-	-	-
Balance as at March 31, 2021	100	-	-	-	100
Profit/(Loss) for the year	-	-	-	-	-
Movement for the year	-	-	-	-	-
Share issue during the year	-	-	-	-	-
Balance as at March 31, 2022	100	-	-	-	100

The accompanying notes form an integral part of financials statements

As per our report of even date

For A.L. Thakkar & Co.
 Firm Registration No.: 120116W
 Chartered Accountants

Sanjiv Shah
 Partner
 Membership No. 042264
 UDIN : 22042254JHJMZ4618


Place: Ahmedabad
 Date: 20.05.2022

For and on behalf of Board of Directors of

Sanjiv Shah
 Sanjiv Shah
 Director
 DIN: 01515296

Aarsh Shah
 Aarsh Shah
 Director
 DIN: 05294294

Place: Ahmedabad
 Date: 20.05.2022



Sakar Oncology Private Limited

CIN:- U24297GJ2020PTC113326

Standalone Notes to Financials statements for the year ended March 31, 2022

	As at March 31, 2022	As at March 31, 2021
4 Other assets		
<u>Non current</u>		
Capital advances	-	-
<u>Current</u>		
Advances to suppliers	-	-
Prepaid Expenses	-	-
Balances with statutory/ Government authorities	-	-
5 Inventories (At lower of cost and Net Realisable Value)	As at March 31, 2022	As at March 31, 2021
Raw material and components:		
Raw Material/Packing Material / Stores & Consumables	-	-
Finished Goods / Stock in Process	-	-
6 Investments	As at March 31, 2022	As at March 31, 2021
<u>Non Current</u>		
Investments at fair value through other comprehensive income (FVTOCI)		
Unquoted equity shares		
Investment in equity share of subsidiary	-	-
<u>Current</u>		
Financial Assets at fair value through Profit or Loss(FVTPL)		
Investment in units of mutual funds - quoted	-	-
7 Trade receivables	As at March 31, 2022	As at March 31, 2021
<u>Current</u>		
Unsecured considered good unless stated otherwise		
- from others	-	-
- from others (Considered Doubtful)	-	-
Notes:		
a) Trade receivable ageing		
Trade receivables ageing schedule for March 31, 2022		
8 Cash and cash equivalents	As at March 31, 2022	As at March 31, 2021
Balances with banks:		
Balance in current account	20.500	20.500
Cash on hand	-	-
	20.500	20.500



Standalone Notes to Financials statements for the year ended March 31, 2022

9 Loans

As at
March 31, 2022

As at
March 31, 2021

Non - Current

Loans and Advance to others (Deposits)
Loans and Advance to Related Parties

- -
- -
- -

Current

Loans to Related Parties (Unsecured) (refer note 34)

- -
- -

10 Share capital

As at
March 31, 2022

As at
March 31, 2021

Authorised

50,00,000 Equity Shares of ` 10 each

50,000.000 50,000.000

50,000.000 50,000.000

Issued, subscribed and fully paid up shares

10000 Equity Shares of ` 10 each

100.000 100.000

100.000 100.000

Notes:

(a) Reconciliation of the number of the shares outstanding as the beginning and end of the year:

	As at March 31, 2022		As at March 31, 2021	
	No in Shares	Amount	No in Shares	Amount
At the beginning of the year	10	100	10.000	100.000
New Shares Issued during the year	-	-	-	-
At the end of the year	10	100	10.000	100.000

(b) Terms/rights attached to equity shares:

The Company has only one class of equity shares having par value of ` 10 per share. Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

(c) Details of shareholder holding more than 5% shares in the Company

Equity shares of ` 10 each fully paid	As at March 31, 2022		As at March 31, 2021	
	No. of Shares	% Holding	No. of Shares	% Holding
Sakar Healthcare Limited	10	100.00%	10.000	1.000
	-	0.00%	-	-
	-	0.00%	-	-

(d) Details of shareholding of Promoters as at March 31, 2022

Promoter name	No. of Shares	% of total shares	% Change during the year
Sakar Healthcare Limited	10	100.00%	-
Total	10	100.00%	-

Details of shareholding of Promoters as at March 31, 2021

Promoter name	No. of Shares in lacs	% of total shares	% Change during the year
Sakar Healthcare Limited	10	100.00%	-
Total	10.00	100.00%	-



Sakar Oncology Private Limited

CIN:- U24297GJ2020PTC113326

Standalone Notes to Financials statements for the year ended March 31, 2022

11 Other equity

	As at March 31, 2022	As at March 31, 2021
Share premium		
Opening Balance		
Movement for the year	-	-
Expense Written Off	-	-
Other Comprehensive Income		
Opening Balance		
Movement for the year	-	-
Deemed Equity Contribution		
Opening Balance		
Movement for the year	-	-
Retained earnings		
Opening Balance		
Add : (Loss) for the year	(852.035)	-
Less: Adjustments	-	(852.035)
Closing balance	(852.035)	(852.035)
Total	(852.035)	(852.035)

12 Other financial liabilities

	As at March 31, 2022	As at March 31, 2021
Current		
Current maturities of long term borrowings	-	-
Note:		

a) Disclosure under Para 44A as set out in Ind AS 7 on cash flow statements under Companies (Indian Accounting Standards) Rules, March 31, 2022

Particulars of liabilities arising from financing activity	Note No.	As at March 31, 2021	Net cash flows	Non Cash Changes		As at March 31, 2022
				Effect due to changes in foreign exchange rates	Others	
Borrowings	18	773	-	-	-	772.535
Total		773	-	-	-	772.535

March 31, 2021

Particulars of liabilities arising from financing activity	Note No.	As at March 31, 2019	Net cash flows	Non Cash Changes		As at March 31, 2020
				Effect due to changes in foreign exchange rates	Others	
Borrowings	18	-	-	-	-	-
Total		-	-	-	-	-

13 Provisions

	As at March 31, 2022	As at March 31, 2021
Non-current		
Provision for gratuity (refer note 36)	-	-
Current		
Provision for gratuity (refer note 36)	-	-



Sakar Oncology Private Limited

CIN:- U24297GJ2020PTC113326

Standalone Notes to Financials statements for the year ended March 31, 2022

14 Deferred tax liabilities/Assets (net)

March 31, 2022 March 31, 2021

Deferred tax liability

Difference between WDV as per books and Income Tax

Deferred tax due to OCI

Deferred tax due to Unamortized Processing Fees

Less: Deferred Tax Assets

Gratuity

MAT credit entitlement

15 Other liabilities

As at
March 31, 2022 As at
March 31, 2021

Current

Advance from customers

For other liabilities

16 Borrowings

As at
March 31, 2022 As at
March 31, 2021

Long term borrowings

Non-current

Secured term loans from Scheduled Banks and Financial Institutions

Less: Unamortised Loan Processing Fees

Secured Car Loan from Bank

Unsecured Loan from directors

Short term borrowings

Working Capital Loan from bank

Total borrowings includes

Secured borrowings

Unsecured borrowings

Total borrowings

17 Trade payables

As at
March 31, 2022 As at
March 31, 2021

Total outstanding dues of micro enterprises and small enterprises (refer note 34)

Total outstanding dues of creditors other than micro enterprises and small enterprises

Notes:

(1) Trade payable ageing

Trade and other payable ageing as on March 31, 2022

Sr No	Particulars	Outstanding for following periods from due date of Payment					Total
		Not Due	Less than 1 year	1-2 years	2-3 Years	More than 3 years	
1	MSME	-	-	-	-	-	-
2	Others	-	-	-	-	-	-
3	Disputed dues - MSME	-	-	-	-	-	-
4	Disputed dues - Others	-	-	-	-	-	-
	Total	-	-	-	-	-	-



Standalone Notes to Financials statements for the year ended March 31, 2022

	As at March 31, 2022	As at March 31, 2021
18 Liability for Current Tax		
Provision for income tax	-	-
	-	-
20 Revenue from operations	For the year ended March 31, 2022	For the year ended March 31, 2021
Sale of products and services		
Domestic Sales	-	-
Export Sales	-	-
	-	-
21 Other Income	For the year ended March 31, 2022	For the year ended March 31, 2021
Interest Income	-	-
Export Incentive	-	-
Profit on Sale of Investment	-	-
Notional Income of Investment	-	-
Exchange Rate Fluctuations	-	-
Vatav & Kasar Income	-	-
Total Other income	-	-
22 Cost of Material and Services	For the year ended March 31, 2022	For the year ended March 31, 2021
Opening stock of Raw Materials and components	-	-
Add: Purchases during the year	-	-
Less: Closing stock of Raw Materials and components	-	-
	-	-
26 Changes in Inventories of Finished Goods and Work-in-Progress		
Opening Stock of Finished Goods / Stock in Process	-	-
Less: Closing Stock of Finished Goods / Stock in Process	-	-
	-	-
27 Employee benefit expense	For the year ended March 31, 2022	For the year ended March 31, 2021
Salaries and wages	-	94.684
Director's Remuneration	-	-
Contribution to provident and other funds	-	-
Contribution to ESIC	-	-
Provision for Gratuity	-	-
Staff welfare expenses	-	-
	-	-
	94.684	
28 Finance costs	For the year ended March 31, 2022	For the year ended March 31, 2021
Interest on		
Interest Expense	-	-
Bank and other finance charges	-	-
	-	-



Standalone Notes to Financials statements for the year ended March 31, 2022

29 Other expenses	For the year ended March 31, 2022	For the year ended March 31, 2021
Company Registration Expense		757.351
	-	757.351
Note: (a)		
Payment to auditor	For the year ended March 31, 2022	For the year ended March 31, 2021
As auditor:		
Audit fee	-	-
Limited review	-	-
	-	-

30 Income tax

The major component of income tax expenses for the year ended March 31, 2022 and March 31, 2021 are as under

a) Profit and loss section

Current income tax:

Current income tax charge

Adjustment in respect of current income tax of previous years

Deferred tax:

Relating to origination and reversal of temporary differences

Tax expense reported in the Statement of profit and loss

	For the year ended March 31, 2022	For the year ended March 31, 2021
	-	-
	-	-
	-	-
	-	-

b) OCI section

Deferred tax related to items recognised in OCI during the year

Net loss/(gain) on remeasurements of defined benefit plans

Income tax charged to OCI

	March 31, 2022	March 31, 2021
		-
	-	-

c) Reconciliation of tax expense and the accounting profit multiplied by India's domestic tax rate for March 31, 2022 and March 31, 2021

Accounting (loss) before taxation

India's domestic tax rate

Tax using the Company's domestic rate

Tax effect of :

Income tax expenses charged to profit and loss

	March 31, 2022	March 31, 2021
	-	(852.035)
	25.17%	25.17%
	-	(214.46)
	-	(214.46)

d) Deferred tax liability (net)

Deferred tax liabilities:

Book V/s tax WDV impact

Income tax effect on re-measurement

gains (losses) on defined benefit plans

MAT Credit Entitlement

Notional Income on Investment

Unamortised Loan Processing Fees

Balance Sheet as at		Statement of Profit and Loss	
March 31, 2022	March 31, 2021	For the year ended March 31, 2022	For the year ended March 31, 2021
	-	-	-
	-	-	-
	-	-	-
	-	-	-
	-	-	-
	-	-	-



31 Financial instruments, financial risk and capital management

31.1 Category-wise classification of financial instruments:

Particulars	Refer note	As at March 31, 2022			
		Fair Value through other Comprehensive Income	Fair Value through other Profit & Loss	Amortised Cost	Carrying value
Financial asset					
Investments					
Trade receivables	6	-	-	-	-
Cash and cash equivalents	7	-	-	-	-
Loans	8	-	-	20,500	20,500
Total	9				
Financial liabilities					
Borrowings					
Trade payables	16	-	-	772,535	772,535
Other financial liabilities	17	-	-	-	-
Total	12				
				772,535	772,535

Particulars	Refer note	As at March 31, 2021			
		Fair Value through other Comprehensive Income	Fair Value through other Profit & Loss	Amortised Cost	Carrying value
Financial asset					
Investments					
Trade receivables	6	-	-	-	-
Cash and cash equivalents	7	-	-	-	-
Loans	8	-	-	20,500	20,500
Total	9				
Financial liabilities					
Borrowings					
Trade payables	16	-	-	772,535	772,535
Other financial liabilities	17	-	-	-	-
Total	12				
				772,535	772,535

Carrying amounts of cash and cash equivalents, trade receivables, investments, unbilled revenues, loans, trade payables and other payables as at March 31, 2022 and March 31, 2021 approximate the fair value because of their short-term nature. Difference between carrying amounts and fair values of bank deposits, other financial assets, other financial liabilities and borrowings subsequently measured at amortised cost is not significant in each of the years presented.

31.2 Financial Instrument measured at amortised cost

The carrying amount of financial assets and financial liabilities measured at amortised cost in the financial statements are a reasonable approximation of their fair values since the Company does not anticipate that the carrying amounts would be significantly different from the values that would eventually be received or settled.

31.3 Fair Value hierarchy

Quantitative disclosures fair value measurement hierarchy for financial assets and financial liabilities:

Particulars	As at March 31, 2022			
	Quoted market prices (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total
Assets				
Investment in Mutual fund (refer note 8)				
Total	-	-	-	-

Particulars	As at March 31, 2021			
	Quoted market prices (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total
Assets				
Investment in Mutual fund (refer note 8)				
Total	-	-	-	-



Standalone Notes to Financials statements for the year ended March 31, 2022

Contractual maturities of financial liabilities as at March 31, 2022	Refer Note	On demand	within 1 year	Over 1 year Within 3 years	Over 3 year Within 5 years	Over 5 year	Total
Borrowings	16	-	-	772.54	-	-	772.535
Other financial liabilities	12	-	-	-	-	-	-
Trade and other payables	17	-	-	-	-	-	-
Total		-	-	772.54	-	-	772.535

Contractual maturities of financial liabilities as at March 31, 2021	Refer Note	On demand	within 1 year	Over 1 year Within 3 years	Over 3 year Within 5 years	Over 5 year	Total
Borrowings	16	-	-	772.54	-	-	772.535
Other financial liabilities	12	-	-	-	-	-	-
Trade and other payables	17	-	-	-	-	-	-
Total		-	-	772.54	-	-	772.535

The table has been drawn up based on the undiscounted contractual maturities of the financial liabilities including interest that will be paid on those liabilities upto the maturity of the instruments.

31.4 Capital management

For the purposes of the company's capital management, capital includes issued capital and all other equity reserves. The primary objective of the company's capital management is to maximize shareholder value. The company manages its capital structure and makes adjustments in the light of changes in economic environment and the requirements of the financial covenants.

The company monitors capital using gearing ratio, which is net debt (total debt less cash and cash equivalents) divided by total capital plus net debt.

Particulars	Refer note	March 31, 2022	March 31, 2021
Total Borrowings	12,16	772.535	772.535
Less: Cash and bank balance	8	20.500	20.500
Net Debt (A)		752.035	752.035
Total Equity (B)	10,11	(752.035)	(752.035)
Total Equity and net debt (C = A + B)		-	-
Gearing ratio		#DIV/0!	#DIV/0!

32 Earnings per share

Earnings attributable to equity shareholders of the Company
Weighted average number of equity shares
Basic and Diluted earning per share (in `)

March 31, 2022 March 31, 2021

- (852.035)
- 10.000
- (85.204)

33 Capital commitments & other commitment

Capital commitments

Particulars	As at March 31, 2022	As at March 31, 2021
Estimated amount of contracts (net of advances) remaining to be executed on capital account and not provided for	-	-

34 Contingent liabilities not provided for

Based on the information available with the Company, there is no contingent liability as at March 31, 2022 (as at March 31, 2021 NIL).

35 Segment information

The Company is primarily engaged in one business segment, namely developing Electronic Manufacturing Cluster as determined by chief operational decision maker, in accordance with Ind AS - 108 "Segment Reporting".

Considering the inter relationship of various activities of the business, the chief operational decision maker monitors the operating results of its business segment on overall basis. Segment performance is evaluated based on profit or loss and is measured consistently with profit or loss in the financial statements.

36 Disclosures as required by Ind AS - 19 Employee Benefits

- a) The company has recognised, in the Statement of Profit and Loss for the current year, an amount of ` 9.60 lacs (previous year ` 9.94 lacs) as expenses under the following defined contribution plan.

Contribution to Provident Fund	2021-22	2020-21
	-	-



Standalone Notes to Financials statements for the year ended March 31, 2022

b) The company has a defined gratuity plan which is unfunded. Under the plan every employee who has completed at least five year of service gets a gratuity on departure at 15 days salary (last drawn salary) for each completed year of service. The following tables summaries the component of the net benefits expense recognised in the statement of profit and loss account and amounts recognized in the balance sheet for the respective plan.

a) Changes in present value of the defined benefit obligation are as follows:

Particulars	March 31, 2022	March 31, 2021
Present value of the defined benefit obligation at the beginning of the year	-	-
Current service cost	-	-
Interest cost	-	-
Re-measurement (or Actuarial) (gain) / loss arising from:	-	-
- change in demographic assumptions	-	-
- change in financial assumptions	-	-
- experience variance	-	-
Benefits paid	-	-
Acquisition Adjustment	-	-
Present value of the defined benefit obligation at the end of the year	-	-

b) Net asset/(liability) recognised in the balance sheet

Particulars	March 31, 2022	March 31, 2021
Contribution to Present value of the defined benefit obligation at the end of the year	-	-
Amount recognised in the balance sheet	-	-
Net (liability)/asset - Current	-	-
Net (liability)/asset - Non-current	-	-

c) Expense recognised in the statement of profit and loss for the year

Particulars	For the year ended March 31, 2022	For the year ended March 31, 2021
Current service cost	-	-
Interest cost on benefit obligation	-	-
Total Expense included in employee benefits expense	-	-

d) Recognised in the other comprehensive income for the year

Particulars	For the year ended March 31, 2022	For the year ended March 31, 2021
Opening Cumulative unrecognized actuarial (gain)/loss	-	-
Actuarial (gain)/losses arising from:	-	-
- change in demographic assumptions	-	-
- change in financial assumptions	-	-
- experience variance	-	-
Recognised in comprehensive income	-	-

e) Maturity profile of Defined Benefit Obligation

Particulars	March 31, 2022	March 31, 2021
Weighted average duration (based on discounted cashflows)	15 years	15 years

Sensitivity Analysis Method

The sensitivity analysis have been determined based on reasonably possible changes of the assumptions occurring at the end of the reporting period, while holding all other assumptions constant.

g) The principle assumptions used in determining gratuity obligations are as follows:

Particulars	March 31, 2022	March 31, 2021
Discount rate	-	-
Rate of escalation in salary (per annum)	-	-
Mortality	As per table of sample mortality from India Assured Lives Mortality (2012-14)	As per table of sample mortality from India Assured Lives Mortality (2012-14)
Attrition rate	-	-

The estimates of future salary increases, considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors, such as supply and demand in the employment market.



37

Information required to be furnished as per Section 22 of the Micro, Small and Medium Enterprises Development Act, 2006 (MSMED Act) and Schedule III of the Companies Act, 2013 for the year ended March 31, 2022.

Sr No	Particulars	Year ended March 31, 2022	Year ended March 31, 2021
1	Principal amount and interest due thereon remaining unpaid to any supplier as at the end of each accounting year.		
	Principal	Nil	Nil
	Interest	Nil	Nil
2	The amount of interest paid by the buyer in terms of section 16, of the Micro Small and Medium Enterprise Development Act, 2006 along with the amounts of the payment made to the supplier beyond the appointed day during each accounting year	Nil	Nil
3	The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under Micro Small and Medium Enterprise Development Act, 2006.	Nil	Nil
4	The amount of interest accrued and remaining unpaid at the end of each accounting year; and	Nil	Nil
5	The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under section 23 of the MSMED Act 2006.	Nil	Nil

38 Standard issued but not effective

As at the date of issue of financial statements, there are no new standards or amendments which have been notified by the MCA but not yet adopted by the Company. Hence, the disclosure is not applicable.

39 Related Parties transactions

Particulars	Name of Company
	Sanjay Shah, Director
Key managerial personnel	Aarsh Shah, Director

Terms and conditions of transactions with related parties

Outstanding balances of related parties at the year-end are unsecured and settlement occurs in cash. There have been no guarantees provided or received for any related party receivables or payables. For the year ended March 31, 2022, the Company has not recorded any impairment of receivables relating to amounts owed by related parties. This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.

Notes:

(i) The names of the related parties and nature of the relationships where control exists are disclosed irrespective of whether or not there have been transactions between the related parties. For others, the names and the nature of relationships is disclosed only when the transactions are entered into by the Company with the related parties during the existence of the related party relationship.

(ii) Aggregate of transactions for the year ended with these parties have been given below.

Transactions	Name of Related Party	March 31, 2022	March 31, 2021
Remuneration Paid	Sanjay Shah, Director	-	-
	Aarsh Shah, Director	-	-
Salary Paid		-	-
Shares Allotted	Sanjay Shah, Director	-	-
€			
Loan Accepted	Aarsh Shah, Director	-	-
Loan Accepted	Sanjay Shah, Director	-	-
Loan Repaid	Sanjay Shah, Director	-	-
Closing Balances		-	-
Unsecured Loan	Sanjay Shah, Director	-	-
	Aarsh Shah, Director	-	-

40 Event occurred after the Balance Sheet Date

The Company evaluates events and transactions that occur subsequent to the balance sheet date but prior to the approval of financial statements to determine the necessity for recognition and/or reporting of any of these events and transactions in the financial statements. As of May 03, 2022, there were no subsequent events to be recognised or reported that are not already disclosed.



Standalone Notes to Financials statements for the year ended March 31, 2022

41 Ratios to be disclosed

Particulars	Items included in numerator and denominator	Ratio as at 31st March, 2022	Ratio as at 31st March, 2021
(a) Current Ratio	Current Assets (including Bank Deposits having maturity of more than 1 year)/ Current Liabilities	Not Applicable	Not Applicable
(b) Debt-Equity Ratio	Net Debt/Total Equity		
(c) Debt Service Coverage Ratio	Earnings before Interest, Depreciation, Tax and Foreign Exchange Loss or (Gain) (net) / (Interest + Finance charges + Repayment of long-term debt made during the period (net of refinance))		
(d) Return on Equity Ratio (refer note 1 below)	Net Profit after Taxes Average Shareholder's Equity		
(e) Inventory turnover ratio	Not Applicable		
(f) Trade Receivables turnover ratio	Revenue from operations Average Trade Receivables	Not Applicable	Not Applicable
(g) Trade payables turnover ratio	Operating expenses + Other expenses Average Trade Payables		
(h) Net capital turnover ratio	Revenue from Operations Net Working capital		
(i) Net profit ratio	Profit after Tax Total Income		
(j) Return on Capital employed	Earnings before Interest, Tax and Foreign Exchange Loss or (Gain) (net)/ Average Capital Employed (Shareholders Fund+Long Term Borrowing+ Current Maturities of Borrowings+Short term borrowings)	Not Applicable	Not Applicable
(k) Return on investment (refer note 2 below)	Profit after tax Average shareholders fund		

Notes

- 1 Due to negative net worth and net loss during the year return on equity ratio is disclosed as Zero.
- 2 Due to loss and negative average shareholders fund return on investment is disclosed as Zero.

42 Previous year figures are regrouped wherever necessary.

The accompanying notes form an integral part of financials statements
As per our report of even date


For A.L. Thakkar & Co.
Firm Registration No.: 120116W
Chartered Accountants


Sanjiv Shah
Partner
Membership No. 042264
UDIN : 22042264AJHJMZ4618

Place: Ahmedabad
Date: 20.05.2022

For and on behalf of Board of Directors of
Sakar Healthcare Limited


Sanjay Shah
Director
DIN: 01515296


Aarsh Shah
Director
DIN: 05294294

Place: Ahmedabad
Date: 20.05.2022

